SynthesisAIDS research and therapy2022
What is polypharmacy in people living with HIV/AIDS? A systematic review.
Synthesis in AIDS research and therapy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 20 citations in OpenAlex.
- Characterizing multimorbidity and the risk for hospitalization among people living with HIV from the African Cohort Study.BMC global and public health · 2026Article
- Assessing biopsychosocial status in people living with HIV: validity, reliability, and responsiveness of BETY-BQ.BMC infectious diseases · 2026Article
- Intersecting social determinants of health, multimorbidity and quality of life in people of Black ethnicities with HIV in South London.AIDS (London, England) · 2025Article
- Improving the care pathway for people living with HIV aged 70 years and older: the impact of geriatric screening in an infectious diseases unit (AUTO-HIV 70).BMC geriatrics · 2025Article
- Balancing polypharmacy and comorbidity management: cardiovascular health.Current opinion in HIV and AIDS · 2025Review
- Prevalence of medication overload among older people with HIV: a MedSafer study.BMC infectious diseases · 2024Article
- Polypharmacy and Aging in People Living with HIV: 6 Years of Experience in a Multidisciplinary Outpatient Clinic.Drugs & aging · 2023Article
- Dual trajectories of antiretroviral therapy adherence and polypharmacy in women with HIV in the United States.AIDS research and therapy · 2023Article
- Factors affecting quality of life in adults with HIV: A local cross-sectional study.The South African journal of physiotherapy · 2023Article
- Barriers and facilitators to maintaining a high level of polypharmacy adherence in people living with HIV: A scoping review.Frontiers in pharmacology · 2023Article
- Cardiometabolic Diseases and Quality-of-Life Outcomes in Adults With HIV in the Deep South: A Cross-sectional Study.The Journal of the Association of Nurses in AIDS Care : JANACArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Polypharmacy in people living with HIV/AIDS (PLWHA) is a rising morbidity that exacts hefty economic burden on health budgets in addition to other adverse clinical outcomes. Despite recent advances, uncertainty remains around its exact definition in PLWHA. In this systematic review and Meta-analysis, we explored relevant databases (PUBMED, EMBASE, CROI) for studies evaluating polypharmacy in PLWHA from January 2000 to August 2021 to ascertain the exact numerical threshold that defines this morbidity. Two independent reviewers extracted and reviewed relevant variables for analyses. The review included a total of 31 studies involving n = 53,347 participants with a mean age of 49.5 (SD ± 17.0) years. There was a total of 36 definitions, with 93.5% defining polypharmacy as the concomitant use of 5 or more medications. We found significant variation in the numerical definition of polypharmacy, with studies reporting it as "minor" (N = 3); "major" (N = 29); "severe" (N = 2); "excessive" (N = 1); and "higher" (N = 1). Most studies did not incorporate a duration (84%) in their definition and excluded ART medications (67.7%). A plurality of studies in PLWHA have established that polypharmacy in this cohort of patients is the intake of ≥ 5 medications (including both ART and non-ART). To standardize the approach to addressing this rising morbidity, we recommend incorporation of this definition into national and international PLWHA treatment guidelines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.